Digital biomarkers are changing the face of clinical trials. By allowing for the collection of high-density data from wearables and apps, we can gain new, more powerful insights into the ability of novel therapeutics to modulate or modify disease. Biospective has performed multiple digital biomarker studies for its sponsors, and we have implemented processes for the acquisition, quality control, and analysis of this “Big Data”.